Provexis
Provexis PLC is a company established in 1999 to bring the tomato extract "FruitFlow" to the market. The "FruitFlow" product has been approved by the European Food Safety Authority as having a positive effect in the prevention of blood platelet aggregation. It was discovered by Professor Asim Duttaroy in 1997 when he was working at the Rowett Institute of Nutrition and Health of Aberdeen University. The company has 75% ownership of NSP#3G, a potential treatment for Crohn's disease, with Liverpool University as the research partner. The company is also researching a potential peptic ulcer treatment in a venture with Manchester University.
Public | |
Traded as | LSE: PXS |
Industry | Food industry |
Headquarters | London, UK |
Revenue | £ unknown |
£Unknown | |
£Unknown | |
Number of employees | 10 |
Website | www.provexis.com |
Since 2008, the largest shareholder in Provexis PLC is DSM Venturing, with a 30% holding. Barclays hold 8%.
Provexis is the owner of the fruit juice brand Sirco. The juice contains the "FruitFlow" tomato extract and is currently available to buy in the United Kingdom.
References